RS
BBIO icon

Rakuten Securities’s BridgeBio Pharma BBIO Stock Holding History

Rakuten Securities’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Buy
+200
New +$14K ﹤0.01% 406
2026
Q1 		– Sell
-66
Closed -$5.05K – 893
2025
Q4 		$5.05K Buy
+66
New +$4.33K ﹤0.01% 516
2025
Q3 		– Sell
-10
Closed -$432 – 911
2025
Q2 		$432 Buy
+10
New +$364 ﹤0.01% 722

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rakuten Securities's BBIO Position: Q2 2026 in Review

Rakuten Securities opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 200 shares worth $14.9K. The stake represents ﹤0.01% of the portfolio and ranks #406 among its holdings. This is a return to the name: Rakuten Securities previously reported a position in BBIO as recently as Q4 2025.

Rakuten Securities first reported a position in BBIO in Q2 2025 and has held it in 3 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Rakuten Securities held 200 shares of BridgeBio Pharma worth $14.9K as of Q2 2026.
  • BridgeBio Pharma was a new Rakuten Securities position in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Rakuten Securities's portfolio in Q2 2026, its #406 holding.
  • Rakuten Securities first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 3 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rakuten Securities's 13F filing for Q2 2026, filed 12 Aug 2026.